Skip to content
PastWins
Presolicitation Full and open

Autoimmune Diseases Statistical & Clinical Coordinating Center (AD-SCCC)

Department of Health and Human Services · National Institutes of Health

Description

Anticipated Period of Performance The anticipated period of performance is February 1, 2027 through January 31, 2028, with an option to extend services for an additional 6 month period, through July 31, 2028. Anticipated award date: February 1, 2027 The NAICS Code is 541715. Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Allergy, Immunology, and Transplantation (DAIT) has a requirement to support a broad range of services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. The major clinical research programs to be supported by this solicitation include, Autoimmunity Centers of Excellence and Immune Tolerance Network (ACE), as well as investigator initiated clinical trials (IICT), and other clinical trials or study activities supported by NIAID herein collectively referred to as NIAID supported research. Description Topic Title: Autoimmune Diseases Statistical & Clinical Coordinating Center (ADSCCC) The Division of Allergy, Immunology, and Transplantation (DAIT), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), project is for work related to the contract below: “Autoimmune Diseases Statistical & Clinical Coordinating Center (AD-SCCC)”, RHO Federal Systems Division, Inc. (Contract 75N93022C00003) This contract was awarded on a competitive basis for a five-year period from February 1, 2022 through January 31, 2027. A term type/level of effort contract was awarded for the delivery of 56,170 direct labor hours per year for Years 1-5. The total value of the contract is $49,268,667 and includes options for extension of the term for a total performance period of 5 years and options for increases in the level of effort, with the purpose of establishing an Autoimmune Diseases Statistical & Clinical Coordinating Center (AD- SCCC) that will provide a broad range of support critical for the design, development, execution, and analysis of clinical research sponsored by NIAID in autoimmune diseases and diseases related to mucosal immunology and primary immune deficiencies. The scope of clinical research to be supported by the AD- SCCC includes: (i) clinical trials at all phases to evaluate the safety and efficacy of investigational products and innovative approaches for disease treatment and prevention; (ii) studies of underlying mechanisms as integral components of clinical trials; (iii) clinical studies (e.g., genetic studies, microbiome studies, surveys of current therapies, etc.); and (iv) surrogate/biomarker studies. The scope of statistical and clinical support functions to be performed by the AD-SCCC includes statistical design and analysis; protocol development; study initiation and management; clinical safety and pharmacovigilance support; safety oversight; management of clinical study collaboration portals; manuscript preparation and management of sample repositories. The NIAID, NIH, conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. The causes, pathogenesis, diagnosis, treatment, and prevention of autoimmune diseases are major areas of emphasis for NIAID’s Division of Allergy, Immunology, and Transplantation (DAIT). DAIT pursues research on autoimmune diseases by supporting investigator-initiated research projects, cooperative clinical studies, national networks of research centers, and demonstration and education research projects. A critical component of the Division’s mission focuses on clinical research to develop new and/or improved strategies to treat or prevent autoimmune diseases through rigorous evaluations of the safety and efficacy of investigational products and therapeutic interventions, studies to elucidate underlying mechanisms of disease, studies to develop and evaluate surrogate/biomarkers of disease stage, severity and progression, and clinical studies of disease natural history. The purpose of this acquisition is to extend the period of performance of the current contract (through July 31, 2028), beginning February 1, 2027, thereby maintaining the same direct labor hours to maintain ongoing clinical trial operations while DAIT completes the competition under the Clinical Data, Safety, and Coordinating Centers (CDSCC) NOFO. The extension retains the existing scope and contract type. The required research and development clinical trial activities are severable in nature, the 18-month extension will be structured as two discrete option periods. Specifically, the Contractor will be responsible for the following: A. Statistical Design Provide expertise, advice and assistance pin the development of statistical design plans for the development of concept and full study proposals for NIAID supported clinical research; Provide assistance in the preparation of concept and full proposals and study-specific protocols; Provide assistance in the preparation of concept and full proposals and protocols for mechanistic studies; Provide support for preclinical safety study evaluation by providing statistical expertise for, and participate in, evaluating the accuracy and validity of data from preclinical safety studies in support of clinical trials if applicable; Provide assistance for clinical trials and mechanistic studies post-study initiation. B. Statistical Analysis Development and preparation of the Statistical Analysis Plan (SAP) for each clinical trial in conjunction with the Study Management Teams (SMTs); Preparation of interim and final analyses; Preparation of summary data reports; Develo

Truncated. Read the full description and attachments on SAM.gov.